Sarcoidosis Drug Global Market Report 2025

The sarcoidosis drug market size is expected to see strong growth in the next few years. It will grow to $10.47 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to the rising prevalence of sarcoidosis, increased awareness of rare and autoimmune diseases, advancements in diagnostic techniques enabling earlier detection, higher healthcare spending, and improved patient access to specialty treatments and biologic therapies. Key trends expected during the forecast period include progress in immunotherapy technologies, the use of artificial intelligence in drug discovery, technological improvements in diagnostic imaging, the development of innovative drug delivery systems, and the incorporation of digital health tools.

The increasing number of clinical trials is expected to drive the growth of the sarcoidosis drug market. Clinical trials are research studies conducted on humans to assess the safety, effectiveness, and side effects of medical treatments or interventions. This rise in clinical trials is fueled by the growing demand for personalized and innovative treatments that require thorough safety and efficacy testing. Sarcoidosis drugs are used in these trials to evaluate their performance in improving patient outcomes and identifying more effective therapies. For example, in November 2023, the Association of the British Pharmaceutical Industry, a trade association based in London, reported a 15% increase in annual recruitment for industry clinical trials in the UK, with participant numbers rising from 36,722 in 2021-22 to 42,088 in 2022-23. As a result, the expanding number of clinical trials is contributing to the growth of the sarcoidosis drug market.

Major companies in the sarcoidosis drug market are focusing on the development of innovative therapies such as anti-TNFα monoclonal antibodies to address treatment-resistant cases and enhance disease management outcomes. These biologic drugs work by blocking tumor necrosis factor-alpha (TNFα), thereby reducing inflammation and tissue damage in conditions like sarcoidosis and other autoimmune diseases. In November 2023, Xentria Inc., a pharmaceutical company based in the US, received orphan drug designation from the European Medicines Agency (EMA) for XTMAB-16, a treatment for sarcoidosis. XTMAB-16 is a chimeric human-murine monoclonal antibody that targets TNFα, a critical inflammatory molecule involved in granuloma formation, which is characteristic of sarcoidosis. The drug is designed to interrupt the inflammatory process and potentially slow granuloma development, especially in pulmonary sarcoidosis, which impacts the lungs.

In June 2023, Xentria Inc. entered into a collaboration with Meitheal Pharmaceuticals Inc. to accelerate the development and commercialization of XTMAB-16. This partnership aims to deliver a targeted and effective treatment for pulmonary sarcoidosis, addressing a significant unmet medical need. Meitheal Pharmaceuticals Inc. is a US-based pharmaceutical manufacturer involved in the production of sarcoidosis drugs.

Major players in the sarcoidosis drug market are AbbVie Inc., Novartis AG., Viatris Inc., Boehringer Ingelheim International GmbH, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mallinckrodt plc, Kyorin Pharmaceutical Co. Ltd., Molecure S.A., aTyr Pharma Inc., Xentria Inc., Relief Therapeutics Holding AG, Foresee Pharmaceuticals Co. Ltd., OrphAI Therapeutics Inc., Bellus Health Inc., AI Therapeutics Inc., Araim Pharmaceuticals Inc., Kinevant Sciences GmbH, SarcoMed USA Inc.

North America was the largest region in the sarcoidosis drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sarcoidosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sarcoidosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sarcoidosis drug market consists of sales of hydroxychloroquine, leflunomide, and cyclophosphamide. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.